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structures vary by IOP threshold values. Day-time IOP control
with PGAs is associated with night-time IOP control whatever
the IOP threshold.
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INTRA-OCULAR PRESSURE CONTROL OF XALACOM ®
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DUOTRAV ® (FIXEDTRAVOPROST ANDTIMOLOL
COMBINATION) IN DAILY PRACTICE
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OBJECTIVES: To conﬁrm, in everyday practice, results from
randomized clinical trials indicating that DuoTrav (a ﬁxed tra-
voprost and timolol combination) controls intra-ocular pressure
(IOP) better than Xalacom (a ﬁxed latanoprost and timolol com-
bination), even when measured >24 hours after last instillation.
METHODS: Patients with ocular hypertension or primary open
angle glaucoma and treated by one of the above combinations
were included in this cross-sectional study. Demographics,
medical history and previous treatments were abstracted from
medical records. IOP and treatment time were collected during
an ofﬁce visit. Analyses of variance, logistic regressions and pro-
pensity scores were used to adjust for confounding factors.
RESULTS: In total, 328 patients were included, 127 treated with
DuoTrav and 201 with Xalacom. The mean age was 64.6 years
and 51.5% were female. Most (275: 84.6%) had last instilled
treatment the previous day. Treatment groups were comparable
except that Xalacom-treated patients had longer disease and
treatment durations. Overall mean IOPs were 24.9 mmHg at
diagnosis and 21.1 mmHg upon starting the ﬁxed combination
treatment. There was no signiﬁcant difference between the groups
as they started their second line therapy. Duotrav-treated patients
experienced better IOP control (17.1 versus 19.1 mmHg:
p < 0.001). A difference was also noted for patients who missed
their last scheduled treatment (17.2 versus 20.1 mmHg:
p < 0.006). Better IOP control with DuoTrav was further sup-
ported by patients whose last instillation was 9.00–12.00 hours
before IOP measurement (16.5 versus 19.3 mmHg; p < 0.001).
According to the practitioners, 83.1% of the DuoTrav-treated
patients attained their IOP targets, as compared to 51.3% of
Xalacom-treated patients (p < 0.001). All these differences per-
sisted after adjustment for confounding factors. CONCLUSION:
This everyday practice study paralled the published correspond-
ing prostaglandin results of Topouzis and DuBiner, i.e. compared
to Xalacom, IOP control with DuoTrav is better and has a longer
residual effect when measured >24 hours later.
EYE—Cost Studies
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OBJECTIVES: The rationale for this study was to provide data
for the German health care system in order to investigate the
assumption that ranibizumab is a cost-effective option for the
treatment of neovascular AMD. METHODS: We modeled cost-
effectiveness for ranibizumab-treatment of the patient’s “better”
eye based on the development of visual acuity in our phase III
studies (ANCHOR/MARINA) compared to a control group who
received best supportive care (e.g. visual aids, regular check-ups).
In the base-case, we computed 6 treatments per year for 2 years
and used the same patient entry age (77 years) and distribution of
visual acuity of the model population as in our phase III studies.
Utility values came from a study by Brazier et al. Costs and
beneﬁts were discounted annually at 5%. Costs of drugs and
treatment procedures were determined based on German phar-
macy retail prices, the German code book for physicians’ fees
(EBM 2000plus) and German DRGs. We conducted a sensitivity
analysis in order to test the stability of our model assumptions.
Variations of the base-case scenario included e.g. patient age:
50–85 years, visual acuity at start of therapy: btw. > 4.0 and
0.05–0.1 or duration of therapy: 1–3 years. RESULTS: The base-
case scenario yielded the following costs per QALY: 16.882 € for
predominantly classic lesions, 24.766 € for minimally classic
chorioidal neovascularization (CNV) and 26.170 € for occult
CNV. When weighing the costs per QALY according to the
distribution of these lesion types (18%–25%–57%), the mean
costs per QALY for the therapy of wet AMD with ranibizumab
amount to 24.147 €. The treatment was cost-effective even under
adverse conditions, e.g. longer treatment duration, high visual
acuity at start of treatment, high patient age, increased costs per
injection. CONCLUSION: Therapy of neovascular AMD with
ranibizumab is cost-effective for all angiographic subtypes
assuming a realistic variation of model parameters.
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OBJECTIVES: Ganfort is a ﬁxed combination product contain-
ing bimatoprost 0.03% and timolol 0.5% indicated for lowering
IOP of patients with glaucoma or ocular hypertension. Other
ﬁxed combination products such as Xalacom (latanoprost
0.005% and timolol 0.5%) and Duotrav (travoprost 0.004%and
timolol 0.5%) are also available on the market. All products have
the advantage of being more convenient for the patient due to
once-daily administration. Since no head to head studies
compare the three combination products, an indirect comparison
is used based on available clinical data. The purpose was to
investigate the cost-effectiveness of the three ﬁxed combination
therapies in eight European countries. METHODS: A systematic
literature search was conducted in order to identify randomized
clinical trials of Duotrav and Xalacom. Studies were selected
which had reduction in IOP as primary endpoint and which were
comparable with data from randomized controlled trials of
Ganfort with respect to study design, diagnosis and patient popu-
lation, so that an indirect comparison could be conducted. A
decision analytic cost-effectiveness model was constructed. The
cost evaluated was cost of medication and clinical visits to an
ophthalmologist. All drug costs are market prices inclusive of
VAT and visit costs are priced using ofﬁcial tariffs. Patients
discontinuing treatment due to adverse events were assumed to
change therapy and had an extra clinical visit. RESULTS: The
cost-effectiveness analysis showed that the cost per percentage
reduction in IOP was least costly for Ganfort. By using Ganfort
therapy, savings per percentage reduction in IOP ranged from
€0.06 to €0.22 compared to Duotrav and €0.02 to €0.36 com-
pared to Xalacom. CONCLUSION: This analysis concludes that
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Ganfort is more cost effective than Duotrav and Xalacom in UK,
Denmark, Sweden, Norway, Finland, France, Italy and Spain.
Thus, the cost per percentage reduction in IOP is lower for
Ganfort compared to Duotrav and Xalacom.
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OBJECTIVES: To assess effectiveness, cost and cost-effectiveness
of Lucentis versus current medical practices in age relatedmacular
degenerescence in France. METHODS: A simulation decision
framework over 1-year time horizon compares a new speciﬁc
agent “Lucentis” versus usual care using two effectiveness end-
points: “vision acuity improvement rate” (greater than 15 letters
at the EDTRS scale) and “rate of legal blindness avoided”. The
two decision trees include various sequences of current therapies
and laser treatment, including or not Lucentis. Data sources come
from clinical data, literature and expert opinions for variability
and uncertainty assumptions. Probabilistic sensitivity analyses
were conducted taking into account speciﬁc distribution laws for
each cost and effectiveness parameters. French costing data
include direct medical costs, adaptative costs and social allowance
in case of blindness. RESULTS: Rate of visual acuity improve-
ment: Lucentis as ﬁrst line agent is signiﬁcantly more effective
(p < 0.001), providing greater treatment success rate of visual
acuity improvement than usual care (48.8% versus 33.9.1%).
Direct medical costs is 9123 Euros over 1 year for Lucentis
compared to 7604 Euros for usual care.Mean cost-effectiveness is
18721 Euros /success for Lucentis versus 22543 Euros/success for
usual care (p < 0.001). Rate of legal blindness avoided: Lucentis as
ﬁrst line agent is signiﬁcantlymore effective (p < 0.001), providing
greater treatment success rate of legal blindness avoided than
usual care (99.6% versus 93.1%). Direct medical costs is 10493
Euros over 1 year for Lucentis compared to 8016 Euros for usual
care. Mean cost-effectiveness is 10526 Euros /legal blindness
avoided for Lucentis versus 8607 Euros/legal blindness avoided
for usual care.CONCLUSION:Lucentis signiﬁcantly improve the
rate of visual acuity improvement and reduces the rate of legal
blindness. Lucentis is signiﬁcantly more cost-effective than usual
care in term of visual acuity improvement.
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OBJECTIVES:To compare the lifetime costs of complications due
to posterior capsule opaciﬁcation after cataract surgery in three
types of IOLs, namely two hydrophobic lenses SA60AT, AR40E
and one hydrophilic lens the XL-Stabi. METHODS: Costs were
estimated from the results of a retrospective study of patients who
underwent cataract surgery in 2001 and 2002 as well as from data
in the literature. Data were analysed after a minimum of 3 years
post-surgery using Kaplan-Meier survival curve analysis with the
end event being time to Nd:Yag laser capsulotomy. Costs were
calculated using two methods of extrapolation. The economic
perspectivewas that of the French Sickness Fund.RESULTS:After
3 years of follow-up, the percentage of patients who had under-
gone Nd:Yag laser capsulotomy was 12.0% with the SA60AT,
25.2% with the AR40E and 51.0% with the XL-Stabi lenses
(P < 0.001). The total cost of capsulotomy and management of
complications per patient lifetimewas estimated to be 142.6 Euros
for SA60AT, 273.4 Euros for AR40E ad 347.1 Euros for XL-Stabi
using the ﬁrst method of extrapolation, while using the second
method of extrapolation, the costs were 242.8, 317.6 and 347.2
Euros, respectively. CONCLUSION: Lower costs for cataract
surgery and management of related complications were observed
with the SA60AT and AR40E IOL’s with the lowest overall costs
being observed in the SA60AT lens.
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OBJECTIVES: Whilst the sight-restoring effects of surgery in
patients with severe bilateral cataract are obvious, there has been
a signiﬁcant trend over the last two decades of performing cata-
ract surgery at an increasingly earlier stage with a rising propor-
tion having 6/12 vision or better at the time of listing. In these
circumstances, the cost-effectiveness of surgery is open to ques-
tion. Therefore, this study evaluated the cost-effectiveness of
ﬁrst-eye cataract surgery compared to no surgery from a Health
Service and Personal Social Services perspective. METHODS: An
economic evaluation was undertaken alongside a randomised
controlled trial of ﬁrst-eye cataract surgery in secondary care
ophthalmology clinics. A total of 306 women over 70 years old
with bilateral cataracts were randomised to cataract surgery
(expedited, approximately 4 weeks) or control (routine, 12
months wait). Seventy-ﬁve percent of participants had baseline
acuity of 6/12 or better. Health and social service contacts were
collected at individual patient level from diaries ascertained at 3
and 9 months via telephone interviews, and at 6 and 12 months
via face-to-face interviews. Outcomes included falls and Quality
Adjusted Life Years (QALYs). RESULTS: The mean difference in
cost between the operated and control group was 2004 (boot-
strapped)(95% CI 1363 to 2833, p < 0.001) over one year
(UK  2004). However, those in the operated group experi-
enced, on average, 0.456 fewer falls, representing an incremental
cost per fall prevented of4390. The bootstrapped mean gain in
QALYs per patient was 0.056 (95% CI 0.006 to 0.108,
p < 0.001). The incremental cost utility ratio was 35,704,
above the currently accepted UK threshold level of willingness to
pay per QALY of30,000. However, in a model of the costs and
beneﬁts over patients’ expected lifetime, the incremental cost per
QALY was 13,172, under conservative assumptions. CON-
CLUSION: First-eye cataract surgery, whilst cost-ineffective over
the trial period, appeared cost-effective over participants’
remaining lifetime.
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OBJECTIVES: After 45–50 years of age, the vast majority of
people have presbyopia, a loss of the ability to focus on near
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